HK1221415A1 - 用於糖尿病治疗的可注射纳米网络凝胶 - Google Patents

用於糖尿病治疗的可注射纳米网络凝胶 Download PDF

Info

Publication number
HK1221415A1
HK1221415A1 HK16109650.4A HK16109650A HK1221415A1 HK 1221415 A1 HK1221415 A1 HK 1221415A1 HK 16109650 A HK16109650 A HK 16109650A HK 1221415 A1 HK1221415 A1 HK 1221415A1
Authority
HK
Hong Kong
Prior art keywords
insulin
particles
formulation
glucose
acid
Prior art date
Application number
HK16109650.4A
Other languages
English (en)
Chinese (zh)
Inventor
G. Anderson Daniel
Gu Zhen
Arthur Aimetti Alex
S. Langer Robert
Original Assignee
Massachusetts Institute Of Technology
The Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology, The Children's Medical Center Corporation filed Critical Massachusetts Institute Of Technology
Publication of HK1221415A1 publication Critical patent/HK1221415A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
HK16109650.4A 2013-04-30 2014-04-29 用於糖尿病治疗的可注射纳米网络凝胶 HK1221415A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361817752P 2013-04-30 2013-04-30
US61/817,752 2013-04-30
US201361864069P 2013-08-09 2013-08-09
US61/864,069 2013-08-09
PCT/US2014/035927 WO2014179344A1 (en) 2013-04-30 2014-04-29 Injectable nano-network gels for diabetes treatment

Publications (1)

Publication Number Publication Date
HK1221415A1 true HK1221415A1 (zh) 2017-06-02

Family

ID=51843897

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16109650.4A HK1221415A1 (zh) 2013-04-30 2014-04-29 用於糖尿病治疗的可注射纳米网络凝胶
HK16110684.2A HK1222546A1 (zh) 2013-04-30 2014-04-29 用於糖尿病治疗的可注射纳米网络凝胶

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16110684.2A HK1222546A1 (zh) 2013-04-30 2014-04-29 用於糖尿病治疗的可注射纳米网络凝胶

Country Status (11)

Country Link
US (1) US20160067190A1 (https=)
EP (1) EP2991673A4 (https=)
JP (1) JP2016517885A (https=)
KR (1) KR20160024853A (https=)
CN (1) CN105813652A (https=)
AU (1) AU2014260024B2 (https=)
BR (1) BR112015027561A8 (https=)
HK (2) HK1221415A1 (https=)
MX (1) MX2015015079A (https=)
RU (1) RU2015151135A (https=)
WO (1) WO2014179344A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
CN104740641B (zh) * 2015-04-08 2019-02-01 烟台大学 一种糖敏感的缓控释微球组合物及其制备方法
RU2719584C2 (ru) * 2015-04-21 2020-04-21 Норт Каролина Стейт Юниверсити Глюкозочувствительная система доставки инсулина с использованием чувствительных к гипоксии нанокомпозитов
JP6757464B2 (ja) * 2016-07-21 2020-09-16 ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． 注射用組成物
WO2018085809A1 (en) 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
EP3799865B1 (en) * 2016-12-05 2022-06-15 North Carolina State University Core-shell microneedle devices and uses thereof
CN106668840B (zh) * 2017-02-10 2020-02-14 南通大学 一种胰岛素控释药物及其制备方法与应用
WO2019055594A1 (en) * 2017-09-13 2019-03-21 North Carolina State University BRUSHING ADIPOSE TISSUE INDUCED LOCALLY BY MICRO-NEEDLE STAMPS FOR THE TREATMENT OF OBESITY
CN111629746B (zh) * 2017-11-21 2024-04-16 北卡罗来纳州立大学 具有超快响应的用于葡萄糖触发胰岛素递送的电荷可切换聚合物储库
EP3735262A4 (en) * 2018-01-03 2021-09-29 Penn State Research Foundation GLUCOSE OXIDASE COMPOSITIONS AS ANTICONVULSIVE FOR NEWBORN
CN111629715A (zh) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 通过调节细胞活化状态改变体内免疫细胞的炎症状态
CN111195238A (zh) * 2018-10-31 2020-05-26 南方医科大学 一种用于胰岛素口服递送的聚电解质复合物
US20220204654A1 (en) * 2019-04-25 2022-06-30 Massachusetts Institute Of Technology Cyclodextrin supramolecular scaffolds and uses thereof
CN115350267B (zh) * 2022-07-19 2025-01-14 深圳大学 一种级联催化型纳米治疗剂及其制备方法和应用
CN115252537B (zh) * 2022-09-01 2026-02-06 西北大学 用于糖尿病伤口的双层微针贴片及其制备方法
CN116474162B (zh) * 2023-04-28 2024-08-16 吉林大学 一种用于糖尿病慢性创伤修复的自修复水凝胶的制备方法
US20250025411A1 (en) * 2023-07-21 2025-01-23 Massachusetts Institute Of Technology Readily soluble and thermostable glucagon formulations and delivery for mini-dosing and closed -loop prophylactic treatment of hypoglycemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6497903B1 (en) * 1996-07-01 2002-12-24 Wilhelmus Everhardus Hennink Hydrolysable hydrogels for controlled release
AU2003301064A1 (en) * 2002-12-17 2004-07-14 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
EP1595534A1 (en) * 2004-05-13 2005-11-16 Universiteit Utrecht Holding B.V. Gel composition comprising charged polymers
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
JP5841708B2 (ja) * 2008-07-01 2016-01-13 日東電工株式会社 表面被覆微粒子の医薬組成物

Also Published As

Publication number Publication date
RU2015151135A (ru) 2017-06-02
CN105813652A (zh) 2016-07-27
JP2016517885A (ja) 2016-06-20
BR112015027561A8 (pt) 2019-12-24
MX2015015079A (es) 2016-07-05
EP2991673A1 (en) 2016-03-09
HK1222546A1 (zh) 2017-07-07
US20160067190A1 (en) 2016-03-10
EP2991673A4 (en) 2016-12-21
WO2014179344A1 (en) 2014-11-06
AU2014260024B2 (en) 2016-09-15
BR112015027561A2 (pt) 2017-07-25
KR20160024853A (ko) 2016-03-07
AU2014260024A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
AU2014260024B2 (en) Injectable nano-network gels for diabetes treatment
Fuchs et al. Hydrogels in emerging technologies for type 1 diabetes
US9339529B2 (en) Glucose-responsive microgels for closed loop insulin delivery
Xie et al. Advances in pH‐sensitive polymers for smart insulin delivery
US20220160841A1 (en) Glucose-responsive insulin delivery microneedle system
Wong Chitosan and its use in design of insulin delivery system
Peng et al. Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin
CN101360486A (zh) 用于蛋白质药物递送的毫微粒
KR20070117564A (ko) 미립자 및 의약품 조성물
Li et al. Advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treatment
US8449915B1 (en) Pharmaceutical composition of nanoparticles
Dehghani et al. An insight into the polymeric nanoparticles applications in diabetes diagnosis and treatment
Verma et al. Nanomaterials for diabetes: diagnosis, detection and delivery
Sona NANOPARTICULATE DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF DIABETES.
Su et al. A review of glucose-responsive particles for insulin delivery as a method of treating type 1 diabetes
SHARMA et al. Recent approaches in glucose responsive insulin delivery system
Patra et al. Stimuli-responsive polymers for treatment of diabetes mellitus
Baieli et al. 3 Biomedical applications of hydrogels in the form of nano-and microparticles
Raj et al. Peptide and protein delivery through carrageenan, alginic acid, agar, and myrrh
Subramani NPDDS for the treatment of diabetes
Fuchs Bioengineering Glucose-Responsive Cannulas for Electronics-Free, Automated Insulin Delivery
CN110179997A (zh) 一种用于糖尿病治疗的纳米药物载体及其组合药物
US20220354966A1 (en) Bioactive nanoparticle compositions and methods for making same
KARGAR FACULTY OF SCIENCE, ENGINEERING AND COMPUTING School of Life Sciences and Pharmacy and Chemistry Department of Chemistry and Pharmacy
US9408917B2 (en) Pharmaceutical composition